Loading [MathJax]/extensions/TeX/boldsymbol.js
Review

Assessing the efficacy of amyotrophic lateral sclerosis drugs in slowing disease progression: A literature review

  • Received: 30 January 2024 Revised: 22 April 2024 Accepted: 28 April 2024 Published: 30 April 2024
  • Amyotrophic lateral sclerosis (ALS) is a fatal and intricate neurodegenerative disease that impacts upper and lower motor neurons within the central nervous system, leading to their progressive destruction. Despite extensive research, the pathogenesis of this multifaceted disease remains elusive. The United States Food and Drug Administration (FDA) has granted approval for seven medications designed to address ALS and mitigate its associated symptoms. These FDA-sanctioned treatments are Qalsody, Relyvrio, Radicava, Rilutek, Tiglutik, Exservan, and Nuedexta. In this review, the effects of these seven drugs on ALS based on their mechanism of action, dosing, and clinical presentations are comprehensively summarized. Each medication offers a distinct approach to manage ALS, aiming to alleviate the burdensome symptoms and slow the disease's progression, thereby improving the quality of life for individuals affected by this neurological condition. However, despite these advancements in pharmaceutical interventions, finding a definitive cure for ALS remains a significant challenge. Continuous investigation into ALS pathophysiology and therapeutic avenues remains imperative, necessitating further research collaborations and innovative approaches to unravel the complex mechanisms underlying this debilitating condition.

    Citation: Ubaid Ansari, Meraj Alam, Dawnica Nadora, Zohaer Muttalib, Vincent Chen, Isabel Taguinod, Megan FitzPatrick, Jimmy Wen, Zaid Ansari, Forshing Lui. Assessing the efficacy of amyotrophic lateral sclerosis drugs in slowing disease progression: A literature review[J]. AIMS Neuroscience, 2024, 11(2): 166-177. doi: 10.3934/Neuroscience.2024010

    Related Papers:

    [1] Yusuf Dogru . η-Ricci-Bourguignon solitons with a semi-symmetric metric and semi-symmetric non-metric connection. AIMS Mathematics, 2023, 8(5): 11943-11952. doi: 10.3934/math.2023603
    [2] Shahroud Azami, Mehdi Jafari, Nargis Jamal, Abdul Haseeb . Hyperbolic Ricci solitons on perfect fluid spacetimes. AIMS Mathematics, 2024, 9(7): 18929-18943. doi: 10.3934/math.2024921
    [3] Xiaosheng Li . New Einstein-Randers metrics on certain homogeneous manifolds arising from the generalized Wallach spaces. AIMS Mathematics, 2023, 8(10): 23062-23086. doi: 10.3934/math.20231174
    [4] Nasser Bin Turki, Sharief Deshmukh, Olga Belova . A note on closed vector fields. AIMS Mathematics, 2024, 9(1): 1509-1522. doi: 10.3934/math.2024074
    [5] Sharief Deshmukh, Mohammed Guediri . Some new characterizations of spheres and Euclidean spaces using conformal vector fields. AIMS Mathematics, 2024, 9(10): 28765-28777. doi: 10.3934/math.20241395
    [6] Amira Ishan . On concurrent vector fields on Riemannian manifolds. AIMS Mathematics, 2023, 8(10): 25097-25103. doi: 10.3934/math.20231281
    [7] Yanlin Li, Aydin Gezer, Erkan Karakaş . Some notes on the tangent bundle with a Ricci quarter-symmetric metric connection. AIMS Mathematics, 2023, 8(8): 17335-17353. doi: 10.3934/math.2023886
    [8] Mohd Danish Siddiqi, Fatemah Mofarreh . Schur-type inequality for solitonic hypersurfaces in (k,μ)-contact metric manifolds. AIMS Mathematics, 2024, 9(12): 36069-36081. doi: 10.3934/math.20241711
    [9] Tong Wu, Yong Wang . Super warped products with a semi-symmetric non-metric connection. AIMS Mathematics, 2022, 7(6): 10534-10553. doi: 10.3934/math.2022587
    [10] Fahad Sikander, Tanveer Fatima, Sharief Deshmukh, Ayman Elsharkawy . Curvature analysis of concircular trajectories in doubly warped product manifolds. AIMS Mathematics, 2024, 9(8): 21940-21951. doi: 10.3934/math.20241066
  • Amyotrophic lateral sclerosis (ALS) is a fatal and intricate neurodegenerative disease that impacts upper and lower motor neurons within the central nervous system, leading to their progressive destruction. Despite extensive research, the pathogenesis of this multifaceted disease remains elusive. The United States Food and Drug Administration (FDA) has granted approval for seven medications designed to address ALS and mitigate its associated symptoms. These FDA-sanctioned treatments are Qalsody, Relyvrio, Radicava, Rilutek, Tiglutik, Exservan, and Nuedexta. In this review, the effects of these seven drugs on ALS based on their mechanism of action, dosing, and clinical presentations are comprehensively summarized. Each medication offers a distinct approach to manage ALS, aiming to alleviate the burdensome symptoms and slow the disease's progression, thereby improving the quality of life for individuals affected by this neurological condition. However, despite these advancements in pharmaceutical interventions, finding a definitive cure for ALS remains a significant challenge. Continuous investigation into ALS pathophysiology and therapeutic avenues remains imperative, necessitating further research collaborations and innovative approaches to unravel the complex mechanisms underlying this debilitating condition.



    In recent years, a useful extension has been proposed from the classical calculus by permitting derivatives and integrals of arbitrary orders is known as fractional calculus. It emerged from a celebrated logical conversation between Leibniz and L'Hopital in 1695 and was enhanced by different scientists like Laplace, Abel, Euler, Riemann, and Liouville [1]. Fractional calculus has gained popularity on the account of diverse applications in various areas of science and technology [2,3,4]. The concept of this new calculus was applied in several distinguished areas previously with excellent developments in the frame of novel approaches and posted scholarly papers, see [5,6,7,8,9,10,11,12,13,14,15,16,17,18]. Various notable generalized fractional integral operators such as the Riemann-Liouville, Hadamard, Caputo, Marichev-Saigo-Maeda, Riez, the Gaussian hypergeometric operators and so on, their attempts helpful for researchers to recognize the real world phenomena. Therefore, the Caputo and Riemann-Liouville was the most used fractional operators having singular kernels. It is remarkable that all the above mentioned operators are the particular cases of the operators investigated by Jarad et al. [19]. The utilities to weighted generalized fractional operators are undertaking now.

    Adopting the excellency of the above work, we introduce a new weighted framework of generalized proportional fractional integral operator with respect to monotone function Ψ. Also, some new characteristics of the aforesaid operator are apprehended to explore new ideas to amplify the fractional operators and acquire fractional integral inequalities via generalized fractional operators (see Remark 2 and 3 below).

    Recently, by employing the fractional integral operators, several researchers have established a bulk of fractional integral inequalities and their variant forms with fertile applications. These sorts of speculations have noteworthy applications in fractional differential/difference equations and fractional Schrödinger equations [20,21]. By the use of Riemann-Liouville fractional integral operator, Belarbi and Dahmani [22] contemplated the subsequent integral inequalities as follows:

    If f1 and g1 are two synchronous functions on [0,), then

    Ωα(f1g1)(ϰ)Γ(α+1)ϰαΩα(f1)(ϰ)Ωα(g1)(ϰ) (1.1)

    and

    ϰαΓ(α+1)Ωβ(f1g1)(ϰ)+ϰβΓ(β+1)Ωα(f1g1)(ϰ)Ωα(f1)(ϰ)Ωβ(g1)(ϰ)+Ωβ(f1)(ϰ)Ωα(g1)(ϰ), (1.2)

    for all ϰ>0,α,β>0. Butt et al. [23], Rashid et al. [24] and Set et al. [25] established the fractional integral inequalities via generalized fractional integral operator having Raina's function, generalized K-fractional integral and Katugampola fractional integral inequalities similar to the variants (1.1) and (1.2), respectively. Here we should emphasize that, inequalities (1.1) and (1.2) are a remarkable instrument for reconnoitering plentiful scientific regions of investigation encompassing probability theory, statistical analysis, physics, meteorology, chaos and henceforth.

    More general version of inequalities (1.1) and (1.2) proposed by Dahmani [26] by employing Riemann-Liouville fractional integral operator.

    Let f1 and g1 be two synchronous functions on [0,) and let r,s:[0,)[0,). Then

    ΩαP(ϰ)Ωα(Qf1g1)(ϰ)+ΩαQ(ϰ)Ωα(Pf1g1)(ϰ)Ωα(Qf1)(ϰ)Ωα(Pg1)(ϰ)+Ωα(Pf1)(ϰ)Ωα(Qg1)(ϰ) (1.3)

    and

    ΩαP(ϰ)Ωβ(Qf1g1)(ϰ)+ΩβQ(ϰ)Ωα(Pf1g1)(ϰ)Ωα(Qf1)(ϰ)Ωβ(Pg1)(ϰ)+Ωβ(Pf1)(ϰ)Ωα(Qg1)(ϰ) (1.4)

    for all ϰ>0,α,β>0. Chinchane and Pachpatte [27], Brahim and Taf [28] and Shen et al. [29] explored the Hadamard fractional integral inequalities, the fractional version of integral inequalities in two variable quantum deformation and the Riemann-Liouville fractional integral operator on time scale analysis coincide to variants (1.3) and (1.4), respectively.

    Let us define the most distinguished Chebyshev functional [30]:

    T(f1,g1)=1b1a1b1a1f1(ϰ)g1(ϰ)dϰ1b1a1b1a1f1(ϰ)dϰ1b1a1b1a1g1(ϰ)dϰ, (1.5)

    where f1 and g1 are two integrable functions on [a1,b1]. In [31], Grüss proposed the well-known generalization:

    |T(f1,g1)|14(Φϕ)(Υγ), (1.6)

    where f1 and g1 are two integrable functions on [a1,b1] satisfying the assumptions

    ϕf1(ϰ)Φ,γg1(ϰ)Υ,ϕ,Φ,γ,ΥR,ϰ[a1,b1]. (1.7)

    The inequality (1.6) is known to be Grüss inequality. In recent years, the Grüss type integral inequality has been the subject of very active research. Mathematicians and scientists can see them in research papers, monographs, and textbooks devoted to the theory of inequalities [32,33,34,35] such as, Dragomir [36] demonstrated certain variants with the supposition of vectors and continuous mappings of selfadjoint operators in Hilbert space similar to (1.6). In this context, f1 and g1 are holding the assumptions (1.7), Dragomir [37] derived several functionals in two and three variable sense as follows:

    |S(f1,g1,P)|14(Φϕ)(Υγ)(b1a1P1(ϰ)dϰ)2, (1.8)

    where

    S(f1,g1,P)=12T(f1,g1,P)=b1a1P(ϰ)dϰb1a1P(ϰ)f1(ϰ)g1(ϰ)dϰb1a1P(ϰ)f1(ϰ)dϰb1a1P(ϰ)g1(ϰ)dϰ (1.9)

    and

    T(f1,g1,P,Q)=b1a1Q(ϰ)dϰb1a1P(ϰ)f1(ϰ)g1(ϰ)dϰ+b1a1P(ϰ)dϰb1a1Q(ϰ)f1(ϰ)g1(ϰ)dϰb1a1Q(ϰ)f1(ϰ)dϰb1a1P(ϰ)g1(ϰ)dϰb1a1P(ϰ)f1(ϰ)dϰb1a1Q(ϰ)g1(ϰ)dϰ. (1.10)

    In [37], Dragomir established the inequality:

    If f1,g1L(a1,b1), then

    |S(f1,g1,P)|f1g1(b1a1P(ϰ)dϰb1a1ϰ2P(ϰ)dϰ(b1a1ϰP(ϰ)dϰ)2). (1.11)

    Moreover, author [37] proved numerous variants for Lipschitzian functions as follows:

    If f1 is L-g1-Lipschitzian on [a1,b1], that is

    |f1(μ)fν|L|g1(μ)g1(ν)|,L>0,μ,ν[a1,b1]. (1.12)

    and

    |S(f1,g1,P)|L(b1a1P(ϰ)dϰb1a1g21(ϰ)P(ϰ)dϰ(b1a1g1(ϰ)P(ϰ)dϰ)2). (1.13)

    Furthermore, if f1 and g1 are L1 and L2-Lipschitzian functions on [a1,b1], then

    |S(f1,g1,P)|L1L2(b1a1P(ϰ)dϰb1a1ϰ2P(ϰ)dϰ(b1a1ϰP(ϰ)dϰ)2). (1.14)

    Owing to the above tendency, Dhamani et al. [38] proposed the fractional integral inequalities in the Riemann-Liouville parallel to variant (1.6) with the suppositions (1.7). Additionally, Dahamani and Benzidane [39] introduced weighted Grüss type inequality via (α,β)-fractional q-integral inequality resemble to (1.8) under the hypothesis of (1.5). Author [40,41] derived the extended functional of (1.10) by employing Riemann-Liouville integral corresponds to variants (1.11), (1.13) and (1.14), respectively. In this flow, Set et al. [42] contemplated the Grüss type inequalities considering the generalized K-fractional integral. Chen et al. [43] obtained the novel refinements of Hermite-Hadamard type inequalities for n-polynomial p-convex functions within the generalized fractional integral operators. Abdeljawad et al. [44] derived the Simpson's type inequalities for generalized p-convex functions involving fractal set. Jarad et al. [45] investigated the properties of the more general form of generalized proportional fractional operators in Laplace transforms.

    The motivation of this paper is twofold. First, we propose a novel framework named weighted generalized proportional fractional integral operator based on characteristics, as well as considering the boundedness and semi-group property and able to be widely applied to many scientific results. Second, the current operator employed to the extended weighted Chebyshev and Grüss type inequalities for exploring the analogous versions of (1.5) and (1.6). Some special cases are pictured with new fractional operators which are not computed yet. Interestingly, particular cases are designed for Riemann-Liouville fractional integral, generalized Riemann-Liouville fractional integral and generalized proportional fractional integral inequalities. It is worth mentioning that these operators have the ability to recapture several generalizations in the literature by considering suitable assumptions of Ψ,ω and ρ.

    In this section, we demonstrate the space where the weighted fractional integrals are bounded and also, provide certain specific features of these operators.

    Definition 2.1 ([19])Let ω0 be a mapping defined on [a1,b1], g1 is a differentiable strictly increasing function on [a1,b1]. The space χpω(a1,b1),1p< is the space of all Lebesgue measurable functions f1 defined on [a1,b1] for which f1χpω, where

    f1χpω=(b1a1|ω(ϰ)f1(ϰ)|pg1(ϰ)dϰ)1p,1<p< (2.1)

    and

    f1χpω=esssupa1ϰb1|ω(ϰ)f1(ϰ)|<. (2.2)

    Remark 1. Clearly we see that f1χpω(a1,b1) ω(ϰ)f1(ϰ)(g11(ϰ))1/pLp(a1,b1) for 1p< and f1χpω(a1,b1) ω(ϰ)f1(ϰ)L(a1,b1).

    Now, we show a novel fractional integral operator which is known as the weighted generalized proportional fractional integral operator with respect to monotone function Ψ.

    Definition 2.2. Let f1χpω(a1,b1) and ω0 be a function on [a1,b1]. Also, assume that Ψ is a continuously differentiable function on [a1,b1] with ψ>0 on [a1,b1]. Then the left and right-sided weighted generalized proportional fractional integral operator with respect to another function Ψ of order α>0 are described as:

    ΨωΩρ;αa1f1(ϰ)=ω1(ϰ)ραΓ(α)ϰa1exp[ρ1ρ(Ψ(ϰ)Ψ(μ))](Ψ(ϰ)Ψ(μ))1αf1(μ)ω(μ)Ψ(μ)dμ,a1<ϰ (2.3)

    and

    ΨωΩρ;αb1f1(ϰ)=ω1(ϰ)ραΓ(α)b1ϰexp[ρ1ρ(Ψ(μ)Ψ(ϰ))](Ψ(μ)Ψ(ϰ))1αf1(μ)ω(μ)Ψ(μ)dμ,ϰ<b1, (2.4)

    where ρ(0,1] is the proportionality index, αC,(α)>0 and Γ(ϰ)=0μϰ1eμdμ is the Gamma function.

    Remark 2. Some particular fractional operators are the special cases of (2.3) and (2.4).

    (1) Setting Ψ(ϰ)=ϰ, in Definition (2.2), then we get the weighted generalized proportional fractional operators stated as follows:

    ωΩρ;αa1f1(ϰ)=ω1(ϰ)ραΓ(α)ϰa1exp[ρ1ρ(ϰμ)](ϰμ)1αf1(μ)ω(μ)dμ,a1<ϰ (2.5)

    and

    ωΩρ;αb1f1(ϰ)=ω1(ϰ)ραΓ(α)b1ϰexp[ρ1ρ(μϰ)](μϰ)1αf1(μ)ω(μ)dμ,ϰ<b1. (2.6)

    (2) Setting Ψ(ϰ)=ϰ and ρ=1 in Definition (2.2), then we get the weighted Riemann-Liouville fractional operators stated as follows:

    ωΩαa1f1(ϰ)=ω1(ϰ)Γ(α)ϰa1f1(μ)ω(μ)dμ(ϰμ)1α,a1<ϰ (2.7)

    and

    ωΩαb1f1(ϰ)=ω1(ϰ)Γ(α)b1ϰf1(μ)ω(μ)dμ(μϰ)1α,ϰ<b1. (2.8)

    (3) Setting Ψ(ϰ)=lnϰ and a1>0 in Definition (2.2), we get the weighted generalized proportional Hadamard fractional operators stated as follows:

    ωΩρ;αa1f1(ϰ)=ω1(ϰ)ραΓ(α)ϰa1exp[ρ1ρ(lnϰμ)](lnϰμ)1αf1(μ)ω(μ)μdμ,a1<ϰ (2.9)

    and

    ωΩρ;αb1f1(ϰ)=ω1(ϰ)ραΓ(α)b1ϰexp[ρ1ρ(lnμϰ)](lnμϰ)1αf1(μ)ω(μ)μdμ,ϰ<b1. (2.10)

    (4) Setting Ψ(ϰ)=lnϰ and a1>0 along with ρ=1 in Definition (2.2), then we get the weighted Hadamard fractional operators stated as follows:

    ωΩαa1f1(ϰ)=ω1(ϰ)Γ(α)ϰa1f1(μ)ω(μ)dμμ(lnϰμ)1α,a1<ϰ (2.11)

    and

    ωΩαb1f1(ϰ)=ω1(ϰ)Γ(α)b1ϰf1(μ)ω(μ)dμμ(lnμϰ)1α,ϰ<b1. (2.12)

    (5) Setting Ψ(ϰ)=ϰττ(τ>0) in Definition (2.2), then we get the weighted generalized fractional operators in terms of Katugampola stated as follows:

    ωΩαa1f1(ϰ)=ω1(ϰ)Γ(α)ϰa1(ϰτμττ)α1f1(μ)ω(μ)dμμ1τ,a1<ϰ (2.13)

    and

    ωΩαb1f1(ϰ)=ω1(ϰ)Γ(α)b1ϰ(μτϰττ)α1f1(μ)ω(μ)dμμ1τ,ϰ<b1. (2.14)

    Remark 3. Several existing integral operators can be derived from Definition 2.2 as follows:

    (1) Letting ω(ϰ)=1, then we get the Definition 4 proposed by Rashid et al. [46] and Definition 3.2 introduced by Jarad et al. [47], independently.

    (2) Letting ω(ϰ)=1,Ψ(ϰ)=ϰ, then we get the Definition 3.4 defined by Jarad et al. [48].

    (3) Letting ω(ϰ)=1 and Ψ(ϰ)=lnϰ along with a1>0, then we get the Definition 2.1 defined by Rahman et al. [49].

    (4) Letting ω(ϰ)=ρ=1 and Ψ(ϰ)=lnϰ along with a1>0, then we get the operator defined by Kilbas et al. [3] and Smako et al. [5], respectively.

    (5) Letting ω(ϰ)=ρ=1 and Ψ(ϰ)=ϰ, then we get the operator defined by Kilbas et al [3].

    (6) Letting ω(ϰ)=1 and Ψ(ϰ)=ϰττ,(τ>0), then we get the operator defined by Katugampola et al. [7].

    (7) Letting ω(ϰ)=ρ=1 and Ψ(ϰ)=ϰτ+sτ+s,τ(0,1],sR, then we get the Definition 2 defined by Khan and Khan et al [50].

    (8) Letting ω(ϰ)=ρ=1 and Ψ(ϰ)=(ϰa1)ττ, and Ψ(ϰ)=(b1ϰ)ττ,(τ>0), then we get the operator defined by Jarad et al. [51].

    Theorem 2.3. For α>0,ρ(0,1],1p and f1χpω(a1,b1). Then ΨωΩρ;αa1 is bounded in χpω(a1,b1) and

    ΨωΩρ;αa1f1χpω(Ψ(b1)Ψ(a1))αf1χpωραΓ(α+1).

    Proof. For 1p, we have

    ΨωΩρ;αa1f1χpω=1ραΓ(α)(b1a1|ϰa1exp[ρ1ρΨ(ϰ)Ψ(μ)](Ψ(ϰ)Ψ(μ))1αω(μ)f1(μ)Ψ(μ)dμ|pΨ(ϰ)dϰ)1/p=1ραΓ(α)(Ψ(b1)Ψ(a1)|t2Ψ(a1)exp[ρ1ρ(t2t1)](t2t1)1αω(Ψ1(t1))f1(Ψ1(t1))|pdt2)1/p.

    Using the fact that |exp[ρ1ρ(t2t1)]|<1. Taking into account the generalized Minkowski inequality [5], we can write

    ΨωΩρ;αa1f1χpω1ραΓ(α)Ψ(b1)Ψ(a1)(|ω(Ψ1(t1))f1(Ψ1(t1))|pΨ(b1)t1(t2t1)p(α1)dt2)1/pdt1=1ραΓ(α)Ψ(b1)Ψ(a1)(|ω(Ψ1(t1))f1(Ψ1(t1))|((Ψ(b1)t1)p(α1)+1p(α1)+1)1/pdt1.

    By employing the well-known Hölder inequality satisfying p1+q1=1, we obtain

    ΨωΩρ;αa1f1χpω1ραΓ(α)(Ψ(b1)Ψ(a1)|ω(Ψ1(t1))f1(Ψ1(t1))|pdt1)1/p(Ψ(b1)Ψ(a1)((Ψ(b1)t1)p(α1)+1p(α1)+1)q/pdt1)1/q1ραΓ(α)(b1a1|ω(ϰ)f1(ϰ)|pΨ(ϰ)dϰ)1/p(Ψ(b1)Ψ(a1)((Ψ(b1)t1)p(α1)+1p(α1)+1)q/pdt1)1/q(Ψ(b1)Ψ(a1))αf1χpωραΓ(α+1).

    Now, for p=, we have

    |ω(ϰ)ΨωΩρ;αa1f1(ϰ)|=1ραΓ(α)ϰa1exp[ρ1ρ(Ψ(ϰ)Ψ(μ))](Ψ(ϰ)Ψ(μ))1αf1(μ)ω(μ)Ψ(μ)dμ1ραΓ(α)ϰa1exp[ρ1ρ(Ψ(ϰ)Ψ(μ))](Ψ(ϰ)Ψ(μ))1α|f1(μ)ω(μ)|Ψ(μ)dμ,Since(|exp[ρ1ρ(t2t1)]|<1)f1χωραΓ(α)ϰa1(Ψ(ϰ)Ψ(μ))α1dμ(Ψ(ϰ)Ψ(a1))αf1χωραΓ(α+1)=(Ψ(b1)Ψ(a1))αf1χωραΓ(α+1).

    This ends the proof.

    Our next result is the semi group property for weighted generalized proportional fractional integral operator with respect to monotone function.

    Theorem 2.4. For α,β>0,ρ(0,1] with 1p and let f1χpω(a1,b1). Then

    (ΨωΩρ;αa1ΨωΩρ;βa1)f1=(ΨωΩρ;α+βa1)f1. (2.15)

    Proof.

    (ΨωΩρ;αa1ΨωΩρ;βa1f1)(ϰ)=ω1(ϰ)ραΓ(α)ϰa1exp[ρ1ρ(Ψ(ϰ)Ψ(μ))](Ψ(ϰ)Ψ(μ))1αω(μ)(ΨωΩρ;βa1f1)(μ)Ψ(μ)dμ=ω1(ϰ)ρα+βΓ(α)Γ(β)ϰa1μa1exp[ρ1ρ(Ψ(ϰ)Ψ(μ))](Ψ(ϰ)Ψ(μ))1αexp[ρ1ρ(Ψ(μ)Ψ(ν))](Ψ(μ)Ψ(ν))1β×ω(ν)f1(ν)Ψ(ν)Ψ(μ)dμdν.

    By making change of variable technique θ=Ψ(μ)Ψ(a1)Ψ(ϰ)Ψ(a1), we can write

    (ΨωΩρ;αa1ΨωΩρ;βa1f1)(ϰ)=ω1(ϰ)ρα+βΓ(α)Γ(β)10θβ1(1θ)α1dθϰa1exp[ρ1ρ(Ψ(ϰ)Ψ(ν))](Ψ(ϰ)Ψ(ν))1αβω(ν)f1(ν)Ψ(ν)dν=ω1(ϰ)ρα+βΓ(α)Γ(β)Γ(α)Γ(β)Γ(α+β)ϰa1exp[ρ1ρ(Ψ(ϰ)Ψ(ν))](Ψ(ϰ)Ψ(ν))1αβω(ν)f1(ν)Ψ(ν)dν=(ΨωΩρ;α+βa1f1)(ϰ),

    where B(α,β)=Γ(α)Γ(β)Γ(α+β)=10θβ1(1θ)α1dθ is known to be Euler Beta function.

    This section contains some significant generalizations for weighted integral inequalities by employing weighted generalized proportional fractional integral operator, for the consequences relating to (1.1) and (1.2), it is suppose that all mappings are integrable in the Riemann sense.

    Throughout this investigation, we use the following assumptions:

    I. Let f1 and g1 be two synchronous functions on [0,).

    II. Let Ψ:[0,)(0,) is an increasing function with continuous derivative Ψ on the interval (0,).

    Lemma 3.1. If the supposition I and II are satisfied and let Q and P be two non-negative continuous mappings on [0,). Then the inequality

    ΨωΩρ;α0+(P)(ϰ)ΨωΩρ;α0+(Qf1g1)(ϰ)+ΨωΩρ;α0+(Pf1g1)(ϰ)ΨωΩρ;α0+(Q)(ϰ)ΨωΩρ;α0+(Pg1)(ϰ)ΨωΩρ;α0+(Qf1)(ϰ)+ΨωΩρ;α0+(Pf1)(ϰ)ΨωΩρ;α0+(Qg1)(ϰ), (3.1)

    holds for all ρ(0,1],αC with (α)>0.

    Proof. Since f1 and g1 are two synchronous functions on [0,), then for all μ>0 and ν>0, we have

    (f1(μ)f1(ν))(g1(μ)g1(ν))0. (3.2)

    By (3.2), we write

    f1(μ)g1(μ)+f1(ν)g1(ν)g1(μ)f1(ν)+g1(ν)f1(μ). (3.3)

    If we multiply both sides of (3.3) by exp[ρ1ρ(Ψ(ϰ)Ψ(μ))]Q(μ)ω(μ)Ψ(μ)ραΓ(α)(Ψ(ϰ)Ψ(μ))1α and integrating the resulting inequality with respect to μ from 0 to ϰ, we get

    1ραΓ(α)ϰ0exp[ρ1ρ(Ψ(ϰ)Ψ(μ))]Q(μ)ω(μ)Ψ(μ)ραΓ(α)(Ψ(ϰ)Ψ(μ))1αf1(μ)g1(μ)dμ+f1(ν)g1(ν)ραΓ(α)ϰ0exp[ρ1ρ(Ψ(ϰ)Ψ(μ))]Q(μ)ω(μ)Ψ(μ)ραΓ(α)(Ψ(ϰ)Ψ(μ))1αdμf1(ν)ραΓ(α)ϰ0exp[ρ1ρ(Ψ(ϰ)Ψ(μ))]Q(μ)ω(μ)Ψ(μ)ραΓ(α)(Ψ(ϰ)Ψ(μ))1αg1(ν)dν+g1(ν)ραΓ(α)ϰ0exp[ρ1ρ(Ψ(ϰ)Ψ(μ))]Q(μ)ω(μ)Ψ(μ)ραΓ(α)(Ψ(ϰ)Ψ(μ))1αf1(μ)dμ. (3.4)

    Taking product both sides of the above equation by ω1(ϰ) and in view of Definition (2.2), we have

    ΨωΩρ;α0+(Qf1g1)(ϰ)+f1(ν)g1(ν)ΨωΩρ;α0+(Q)(ϰ)g1(ν)ΨωΩρ;α0+(Qf1)(ϰ)+f1(ν)ΨωΩρ;α0+(Qg1)(ϰ). (3.5)

    Further, if we multiply both sides of (3.5) by exp[ρ1ρ(Ψ(ϰ)Ψ(ν))]P(ν)ω(ν)Ψ(ν)ραΓ(α)(Ψ(ϰ)Ψ(ν))1α and integrating the resulting inequality with respect to ν from 0 to ϰ. Then, multiplying by ω1(ϰ) and in view of Definition 2.2, we obtain

    ΨωΩρ;α0+(P)(ϰ)ΨωΩρ;α0+(Qf1g1)(ϰ)+ΨωΩρ;α0+(Pf1g1)(ϰ)ΨωΩρ;α0+(Q)(ϰ)ΨωΩρ;α0+(Pg1)(ϰ)ΨωΩρ;α0+(Qf1)(ϰ)+ΨωΩρ;α0+(Pf1)(ϰ)ΨωΩρ;α0+(Qg1)(ϰ), (3.6)

    which implies (3.1).

    Theorem 3.2. Under the assumption of I, II and let r, s and t be three non-negative continuous functions on [0,). Then the inequality

    2ΨωΩρ;α0+r(ϰ)(ΨωΩρ;α0+s(ϰ)ΨωΩρ;α0+(tf1g1)(ϰ)+ΨωΩρ;α0+(sf1g1)(ϰ)ΨωΩρ;α0+t(ϰ))+2ΨωΩρ;α0+(rf1g1)(ϰ)ΨωΩρ;α0+s(ϰ)ΨωΩρ;α0+t(ϰ)ΨωΩρ;α0+r(ϰ)(ΨωΩρ;α0+(sg1)(ϰ)ΨωΩρ;α0+(tf1)(ϰ)+ΨωΩρ;α0+(sf1)(ϰ)ΨωΩρ;α0+(tg1)(ϰ))+ΨωΩρ;α0+s(ϰ)(ΨωΩρ;α0+(rg1)(ϰ)ΨωΩρ;α0+(tf1)(ϰ)+ΨωΩρ;α0+(rf1)(ϰ)ΨωΩρ;α0+(tg1)(ϰ))+ΨωΩρ;α0+s(ϰ)(ΨωΩρ;α0+(sg1)(ϰ)ΨωΩρ;α0+(rf1)(ϰ)+ΨωΩρ;α0+(sf1)(ϰ)ΨωΩρ;α0+(rg1)(ϰ)) (3.7)

    holds for all ρ(0,1],αC with (α)>0.

    Proof. By means of Lemma 3.1 and setting P=r,Q=s, we can write

    ΨωΩρ;α0+s(ϰ)ΨωΩρ;α0+(tf1g1)(ϰ)+ΨωΩρ;α0+(sf1g1)(ϰ)ΨωΩρ;α0+t(ϰ)ΨωΩρ;α0+(sg1)(ϰ)ΨωΩρ;α0+(tf1)(ϰ)+ΨωΩρ;α0+(sf1)(ϰ)ΨωΩρ;α0+(tg1)(ϰ). (3.8)

    Conducting product both sides of (3.8) by ΨωΩρ;α0+r(ϰ), we obtain

    ΨωΩρ;α0+r(ϰ)(ΨωΩρ;α0+s(ϰ)ΨωΩρ;α0+(tf1g1)(ϰ)+ΨωΩρ;α0+(sf1g1)(ϰ)ΨωΩρ;α0+t(ϰ))ΨωΩρ;α0+r(ϰ)(ΨωΩρ;α0+(sg1)(ϰ)ΨωΩρ;α0+(tf1)(ϰ)+ΨωΩρ;α0+(sf1)(ϰ)ΨωΩρ;α0+(tg1)(ϰ)). (3.9)

    By means of Lemma 3.1 and setting P=r,Q=t, we can write

    ΨωΩρ;α0+r(ϰ)ΨωΩρ;α0+(tf1g1)(ϰ)+ΨωΩρ;α0+(rf1g1)(ϰ)ΨωΩρ;α0+t(ϰ)ΨωΩρ;α0+(rg1)(ϰ)ΨωΩρ;α0+(tf1)(ϰ)+ΨωΩρ;α0+(rf1)(ϰ)ΨωΩρ;α0+(tg1)(ϰ). (3.10)

    Conducting product of (3.10) by ΨωΩρ;α0+s(ϰ), we obtain

    ΨωΩρ;α0+s(ϰ)(ΨωΩρ;α0+r(ϰ)ΨωΩρ;α0+(tf1g1)(ϰ)+ΨωΩρ;α0+(rf1g1)(ϰ)ΨωΩρ;α0+t(ϰ))ΨωΩρ;α0+s(ϰ)(ΨωΩρ;α0+(rg1)(ϰ)ΨωΩρ;α0+(tf1)(ϰ)+ΨωΩρ;α0+(rf1)(ϰ)ΨωΩρ;α0+(tg1)(ϰ)). (3.11)

    By similar argument as we did before, yields

    ΨωΩρ;α0+t(ϰ)(ΨωΩρ;α0+r(ϰ)ΨωΩρ;α0+(sf1g1)(ϰ)+ΨωΩρ;α0+(rf1g1)(ϰ)ΨωΩρ;α0+t(ϰ))ΨωΩρ;α0+s(ϰ)(ΨωΩρ;α0+(sg1)(ϰ)ΨωΩρ;α0+(rf1)(ϰ)+ΨωΩρ;α0+(sf1)(ϰ)ΨωΩρ;α0+(rg1)(ϰ)). (3.12)

    Adding (3.9), (3.11) and (3.12), we get the desired inequality (3.8).

    Lemma 3.3. Under the assumption of I, II and let Q and P be two non-negative continuous functions on [0,). Then the inequality

    ΨωΩρ;α0+(Pf1g1)(ϰ)ΨωΩρ;β0+Q(ϰ)+ΨωΩρ;α0+P(ϰ)ΨωΩρ;β0+(Qf1g1)(ϰ)ΨωΩρ;α0+(Pf1)(ϰ)ΨωΩρ;β0+(Qg1)(ϰ)+ΨωΩρ;α0+(Pg1)(ϰ)ΨωΩρ;β0+(Qf1)(ϰ),

    holds for all ρ(0,1],α,βC with (α),(β)>0.

    Proof. If we multiply both sides of (3.2) by exp[ρ1ρ(Ψ(ϰ)Ψ(ν))]Q(ν)ω(ν)Ψ(ν)ρβΓ(β)(Ψ(ϰ)Ψ(ν))1β and integrating the resulting inequality with respect to ν from 0 to ϰ, we have

    f1(μ)g1(μ)ρβΓ(β)ϰ0exp[ρ1ρ(Ψ(ϰ)Ψ(ν))]Q(ν)ω(ν)Ψ(ν)(Ψ(ϰ)Ψ(ν))1βdν+f1(ν)g1(ν)ρβΓ(β)ϰ0exp[ρ1ρ(Ψ(ϰ)Ψ(ν))]Q(ν)ω(ν)Ψ(ν)(Ψ(ϰ)Ψ(ν))1βdνg1(μ)ρβΓ(β)ϰ0exp[ρ1ρ(Ψ(ϰ)Ψ(ν))]Q(ν)ω(ν)Ψ(ν)(Ψ(ϰ)Ψ(ν))1βf1(ν)dν+f1(μ)ρβΓ(β)ϰ0exp[ρ1ρ(Ψ(ϰ)Ψ(ν))]Q(ν)ω(ν)Ψ(ν)(Ψ(ϰ)Ψ(ν))1βg1(ν)dν. (3.13)

    Taking product both sides of the above equation by ω1(ϰ) and in view of Definition (2.2), we have

    f1(μ)g1(μ)ΨωΩρ;β0+Q(ϰ)+ΨωΩρ;β0+(Qf1g1)(ϰ)f1(μ)ΨωΩρ;β0+(Qg1)(ϰ)+g1(μ)ΨωΩρ;β0+(Qf1)(ϰ). (3.14)

    Again, multiplying both sides of (3.14) by exp[ρ1ρ(Ψ(ϰ)Ψ(μ))]P(μ)ω(μ)Ψ(μ)ραΓ(α)(Ψ(ϰ)Ψ(μ))1α and integrating the resulting inequality with respect to ν from 0 to ϰ, we have

    ΨωΩρ;β0+Q(ϰ)ραΓ(α)ϰ0exp[ρ1ρ(Ψ(ϰ)Ψ(μ))]P(μ)ω(μ)Ψ(μ)(Ψ(ϰ)Ψ(μ))1αf1(μ)g1(μ)dμ+ΨωΩρ;β0+(Qf1g1)(ϰ)ραΓ(α)ϰ0exp[ρ1ρ(Ψ(ϰ)Ψ(μ))]P(μ)ω(μ)Ψ(μ)(Ψ(ϰ)Ψ(μ))1αdμΨωΩρ;β0+(Qg1)(ϰ)ραΓ(α)ϰ0exp[ρ1ρ(Ψ(ϰ)Ψ(μ))]P(μ)ω(μ)Ψ(μ)(Ψ(ϰ)Ψ(μ))1αf1(μ)dμ+ΨωΩρ;β0+(Qf1)(ϰ)ραΓ(α)ϰ0exp[ρ1ρ(Ψ(ϰ)Ψ(μ))]P(μ)ω(μ)Ψ(μ)(Ψ(ϰ)Ψ(μ))1αg1(μ)dμ. (3.15)

    Taking product both sides of the above equation by ω1(ϰ) and in view of Definition (2.2), we obtain

    ΨωΩρ;α0+(Pf1g1)(ϰ)ΨωΩρ;β0+Q(ϰ)+ΨωΩρ;α0+P(ϰ)ΨωΩρ;β0+(Qf1g1)(ϰ)ΨωΩρ;α0+(Pf1)(ϰ)ΨωΩρ;β0+(Qg1)(ϰ)+ΨωΩρ;α0+(Pg1)(ϰ)ΨωΩρ;β0+(Qf1)(ϰ),

    which implies (3.13).

    Theorem 3.4. Under the assumptions I, II and let r, s and t be three non-negative continuous functions on [0,). Then the inequality

    ΨωΩρ;α0+r(ϰ)(ΨωΩρ;α0+(sf1g1)(ϰ)ΨωΩρ;β0+t(ϰ)+2ΨωΩρ;α0+s(ϰ)ΨωΩρ;β0+(tf1g1)(ϰ)+ΨωΩρ;β0+t(ϰ)ΨωΩρ;α0+(sf1g1)(ϰ))+(ΨωΩρ;β0+t(ϰ)ΨωΩρ;α0+s(ϰ)+ΨωΩρ;α0+t(ϰ)ΨωΩρ;β0+s(ϰ))ΨωΩρ;α0+(rf1g1)(ϰ)ΨωΩρ;α0+r(ϰ)(ΨωΩρ;α0+(sf1)(ϰ)ΨωΩρ;β0+(tg1)(ϰ)+ΨωΩρ;α0+(sg1)(ϰ)ΨωΩρ;β0+(tf1)(ϰ))+ΨωΩρ;α0+s(ϰ)(ΨωΩρ;α0+(rf1)(ϰ)ΨωΩρ;β0+(tg1)(ϰ)+ΨωΩρ;α0+(rg1)(ϰ)ΨωΩρ;β0+(tf1)(ϰ))+ΨωΩρ;α0+t(ϰ)(ΨωΩρ;α0+(rf1)(ϰ)ΨωΩρ;β0+(sg1)(ϰ)+ΨωΩρ;α0+(rg1)(ϰ)ΨωΩρ;β0+(sf1)(ϰ)) (3.16)

    holds for all ρ(0,1],α,βC with (α),(β)>0.

    Proof. By means of Lemma 3.3 and setting P=s,Q=t, we can write

    ΨωΩρ;α0+(sf1g1)(ϰ)ΨωΩρ;β0+t(ϰ)+ΨωΩρ;α0+s(ϰ)ΨωΩρ;β0+(tf1g1)(ϰ)ΨωΩρ;α0+(sf1)(ϰ)ΨωΩρ;β0+(tg1)(ϰ)+ΨωΩρ;α0+(sg1)(ϰ)ΨωΩρ;β0+(tf1)(ϰ). (3.17)

    Conducting product both sides of (3.17) by ΨωΩρ;α0+r(ϰ), we obtain

    ΨωΩρ;α0+r(ϰ)(ΨωΩρ;α0+(sf1g1)(ϰ)ΨωΩρ;β0+t(ϰ)+ΨωΩρ;α0+s(ϰ)ΨωΩρ;β0+(tf1g1)(ϰ))ΨωΩρ;α0+r(ϰ)(ΨωΩρ;α0+(sf1)(ϰ)ΨωΩρ;β0+(tg1)(ϰ)+ΨωΩρ;α0+(sg1)(ϰ)ΨωΩρ;β0+(tf1)(ϰ)). (3.18)

    Again, by means of Lemma 3.3 and setting P=r,Q=t, we can write

    ΨωΩρ;α0+(rf1g1)(ϰ)ΨωΩρ;β0+t(ϰ)+ΨωΩρ;α0+r(ϰ)ΨωΩρ;β0+(tf1g1)(ϰ)ΨωΩρ;α0+(rf1)(ϰ)ΨωΩρ;β0+(tg1)(ϰ)+ΨωΩρ;α0+(rg1)(ϰ)ΨωΩρ;β0+(tf1)(ϰ). (3.19)

    Conducting product both sides of (3.19) by ΨωΩρ;α0+s(ϰ), we obtain

    ΨωΩρ;α0+s(ϰ)(ΨωΩρ;α0+(rf1g1)(ϰ)ΨωΩρ;β0+t(ϰ)+ΨωΩρ;α0+r(ϰ)ΨωΩρ;β0+(tf1g1)(ϰ))ΨωΩρ;α0+s(ϰ)(ΨωΩρ;α0+(rf1)(ϰ)ΨωΩρ;β0+(tg1)(ϰ)+ΨωΩρ;α0+(rg1)(ϰ)ΨωΩρ;β0+(tf1)(ϰ)). (3.20)

    By similar arguments as we did before, yields

    ΨωΩρ;α0+t(ϰ)(ΨωΩρ;α0+(sf1g1)(ϰ)ΨωΩρ;β0+r(ϰ)+ΨωΩρ;α0+s(ϰ)ΨωΩρ;β0+(rf1g1)(ϰ))ΨωΩρ;α0+t(ϰ)(ΨωΩρ;α0+(rf1)(ϰ)ΨωΩρ;β0+(sg1)(ϰ)+ΨωΩρ;α0+(rg1)(ϰ)ΨωΩρ;β0+(sf1)(ϰ)). (3.21)

    Adding (3.18), (3.20) and (3.21), we get the desired inequality (3.16).

    Remark 4. Theorem 3.2 and Theorem 3.4 lead to the following conclusions:

    (1) Let f1 and g1 are the asynchronous functions on [0,), then (3.8) and (3.16) are reversed.

    (2) Let r,s and t are negative on [0,), then (3.8) and (3.16) are reversed.

    (3) Let r,s are positive t is negative on [0,), then (3.8) and (3.16) are reversed.

    In the next, we derive certain novel Grüss-type integral inequalities via weighted generalized proportional fractional integral operators.

    Lemma 3.5. Suppose an integrable function f1 defined on [0,) satisfying the assertions I,II and (1.7) on [0,) and let a continuous function r defined on [0,). Then the inequality

    ΨωΩρ;α0+r(ϰ)ΨωΩρ;α0+(rf21)(ϰ)(ΨωΩρ;α0+(rf1)(ϰ))2(ΦΨωΩρ;α0+x(ϰ)ΨωΩρ;α0+(rf1)(ϰ))(ΨωΩρ;α0+(rf1)(ϰ)ϕΨωΩρ;α0+r(ϰ))ΨωΩρ;α0+r(ϰ)ΨωΩρ;α0+(r(ϰ)(Φf1(ϰ))(f1(ϰ)ϕ)) (3.22)

    holds for all ρ(0,1],αC with (α)>0.

    Proof. By the given hypothesis and utilizing (1.7). For any μ,ν[0,), we have

    (Φf1(ν))(f1(μ)ϕ)+(Φf1(μ))(f1(ν)ϕ)(Φf1(μ))(f1(μ)ϕ)(Φf1(ν))(f1(ν)ϕ)f21(μ)+f21(ν)2f1(μ)f1(ν). (3.23)

    Multiplying both sides of (3.23) by exp[ρ1ρ(Ψ(ϰ)Ψ(ν))]r(ν)ω(ν)Ψ(ν)ραΓ(α)(Ψ(ϰ)Ψ(ν))1α and integrating the resulting inequality with respect to ν from 0 to ϰ, we have

    (f1(μ)ϕ)ραΓ(α)ϰ0exp[ρ1ρ(Ψ(ϰ)Ψ(ν))]r(ν)ω(ν)Ψ(ν)(Ψ(ϰ)Ψ(ν))1α(Φf1(ν))dν+(Φf1(μ))ραΓ(α)ϰ0exp[ρ1ρ(Ψ(ϰ)Ψ(ν))]r(ν)ω(ν)Ψ(ν)(Ψ(ϰ)Ψ(ν))1α(f1(ν)ϕ)dν(Φf1(μ))(f1(μ)ϕ)ραΓ(α)ϰ0exp[ρ1ρ(Ψ(ϰ)Ψ(ν))]r(ν)ω(ν)Ψ(ν)(Ψ(ϰ)Ψ(ν))1αdν1ραΓ(α)ϰ0exp[ρ1ρ(Ψ(ϰ)Ψ(ν))]r(ν)ω(ν)Ψ(ν)(Ψ(ϰ)Ψ(ν))1α(Φf1(ν))(f1(ν)ϕ)dνf21(μ)ραΓ(α)ϰ0exp[ρ1ρ(Ψ(ϰ)Ψ(ν))]r(ν)ω(ν)Ψ(ν)(Ψ(ϰ)Ψ(ν))1αdν+1ραΓ(α)ϰ0exp[ρ1ρ(Ψ(ϰ)Ψ(ν))]r(ν)ω(ν)Ψ(ν)(Ψ(ϰ)Ψ(ν))1αf21(ν)dν2f1(μ)ραΓ(α)ϰ0exp[ρ1ρ(Ψ(ϰ)Ψ(ν))]r(ν)ω(ν)Ψ(ν)(Ψ(ϰ)Ψ(ν))1αf1(ν)dν. (3.24)

    Taking product both sides of the above equation by and in view of Definition (2.2), we obtain

    (3.25)

    Multiplying both sides of (3.25) by and integrating the resulting inequality with respect to from to we have

    (3.26)

    Taking product both sides of the above equation by and in view of Definition (2.2), we obtain

    (3.27)

    which gives (3.22) and proves the lemma.

    Theorem 3.6. Suppose two integrable functions and defined on satisfying the assertions and on and let a continuous function defined on . Then the inequality

    (3.28)

    holds for all with

    Proof. By the given hypothesis stated in Theorem 3.6. Also, assume that be defined by

    (3.29)

    Multiplying both sides of (3.30) by and integrating the resulting inequality with respect to and from to we can state that

    (3.30)

    Taking product both sides of the above equation by and in view of Definition (2.2), we obtain

    (3.31)

    Thanks to the weighted Cauchy-Schwartz integral inequality for double integrals, we can write that

    (3.32)

    Since and we have

    (3.33)

    and

    (3.34)

    Therefore, from (3.33), (3.34) and Lemma 3.5, we get

    (3.35)

    and

    (3.36)

    Combining (3.30), (3.31), (3.35) and (3.36), we deduce that

    (3.37)

    Taking into consideration the elementary inequality we can state that

    (3.38)

    and

    (3.39)

    From (3.37)-(3.39), we obtain (3.28). This completes the proof of Theorem 3.6.

    Lemma 3.7. Suppose two integrable functions and defined on satisfying the assertions and on and let two continuous function and defined on . Then the inequality

    (3.40)

    holds for all with

    Proof. Taking product (3.30) by and integrating the resulting inequality with respect to and from to we can state that

    (3.41)

    Taking product both sides of the above equation by and utilizing Definition (2.2), we have

    (3.42)

    Then, thanks to the weighted Cauchy-Schwartz integral inequality for double integrals, we conclude (3.40).

    Lemma 3.8. Suppose an integrable function defined on satisfying the assertions and on and let two continuous function and defined on . Then the inequality

    (3.43)

    holds for all with

    Proof. Multiplying both sides of (3.25) by and integrating the resulting inequality with respect to from to Then, by multiplying with and in view of Definition 2.2, concludes

    (3.44)

    which gives (3.43) and proves the lemma.

    Theorem 3.9. Suppose two integrable functions and defined on satisfying the assertions and on and let two continuous function and defined on . Then the inequality

    (3.45)

    holds for all with

    Proof. Since and we have

    (3.46)

    and

    (3.47)

    Utilizing Lemma 3.8 to and and utilizing Lemma 3.7 and the inequalities (3.46) and (3.47), yields (3.45).

    Theorem 3.10. Suppose two integrable functions and defined on satisfying the assertions and on and let two continuous function and defined on . Then the inequality

    (3.48)

    holds for all with

    Proof. Taking into consideration the assumption (1.7), we have

    (3.49)

    which implies that

    (3.50)

    From (3.42) and (3.50), we obtain that

    (3.51)

    This ends the proof.

    Theorem 3.11. Suppose two integrable functions and defined on satisfying the assertions and on and let two continuous function and defined on . Then the inequality

    (3.52)

    holds for all with

    Proof. Taking into consideration the assumption (1.12), we have

    (3.53)

    which implies that

    (3.54)

    From (3.42) and (3.54), we obtain that

    (3.55)

    This ends the proof.

    Theorem 3.12. Suppose two integrable functions and defined on satisfying the assertions and the lipschitzian condition with the constants and and let two continuous function and defined on . Then the inequality

    (3.56)

    holds for all with

    Proof. By the given hypothesis, we have

    (3.57)

    which implies that

    (3.58)

    From (3.42) and (3.58), we obtain that

    (3.59)

    This ends the proof.

    Corollary 1. Let and be two differentiable functions on and let and be two non-negative continuous functions on Then the inequality

    (3.60)

    holds for all with

    Proof. We have and That is, and the immediate consequence follows from Theorem 3.12. This completes the proof.

    Example 3.13. Let with and be a function on Let be an integrable function defined on and be the weighted generalized proportional fractional integral operator satisfying assumption Then we have

    where

    and

    is the incomplete gamma function [52,53].

    Proof. It follows from Definition 2.2 and the modulus property that

    for

    Making use of the well-known Hölder inequality, we obtain

    Let Then elaborated computations lead to

    Here, we aim at present some new generalizations via weighted generalized proportional fractional, weighted generalized Riemann-Liouville and weighted Riemann-Liouville fractional integral operators, which are the new estimates of the main consequences.

    Lemma 4.1. Let and be two synchronous functions on Assume that and be two non-negative continuous mappings on Then the inequality

    holds for all with

    Proof. Letting and Lemma 3.1 yields the proof of Lemma 4.1.

    Lemma 4.2. Let and be two synchronous functions on Assume that and be two non-negative continuous mappings on Then the inequality

    holds for all with

    Proof. Letting and Lemma 3.1 yields the proof of Lemma 4.2.

    Lemma 4.3. Under the assumption of Lemma 3.1, then the inequality

    holds for all with

    Proof. Letting and Lemma 3.1 yields the proof of Lemma 4.3.

    Lemma 4.4. Under the assumption of Lemma 4.2, then the inequality

    holds for all with

    Proof. Letting and Lemma 3.1 yields the proof of Lemma 4.4.

    Theorem 4.5. Let and be two synchronous functions on Assume that and be three non-negative continuous functions on Then the inequality

    holds for all with

    Proof. Letting and Theorem 3.2 yields the proof of Theorem 4.5.

    Theorem 4.6. Under the assumption of and let and be three non-negative continuous functions on Then the inequality

    holds for all with

    Proof. Letting and Theorem 3.2 yields the proof of Theorem 4.6.

    Theorem 4.7. Under the assumption of Theorem 4.5, then the inequality

    holds for all with

    Proof. Letting and Theorem 3.2 yields the proof of Theorem 4.7.

    Remark 5. The computed results lead to the following conclusion:

    (1) Setting and and using the relation (2.7), (2.8) and the assumption , then Theorem 3.6 and Theorem 3.9 reduces to the known results due to Dahmani et al. [38].

    (2) Setting and using the relation (2.7), (2.8) and the assumption , then Theorem 3.10–3.12, and Corollary 1 reduces to the known results due to Dahmani et al. [38] and Dahmani [40], respectively.

    A new generalized fractional integral operator is proposed in this paper. The novel investigation is used to generate novel weighted fractional operators in the Riemann-Liouville, generalized Riemann-Liouville, Hadamard, Katugampola, Generalized proportional fractional, generalized Hadamard proportional fractional and henceforth, which effectively alleviates the adverse effect of another function and proportionality index Utilizing the weighted generalized proportional fractional operator technique, we derived the analogous versions of the extended Chebyshev and Grüss type inequalities that improve the accuracy and efficiency of the proposed technique. Contemplating the Remark 2 and 3, several existing results can be identified in the literature. Some innovative particular cases constructed by this method are tested and analyzed for statistical theory, fractional Schrödinger equation [20,21]. The results show that the method proposed in this paper can stably and efficiently generate integral inequalities for convexity with better operators performance, thus providing a reliable guarantee for its application in control theory [54].

    The authors declare that they have no competing interests.

    The authors would like to express their sincere thanks to referees for improving the article and also thanks to Natural Science Foundation of China (Grant Nos. 61673169) for providing financial assistance to support this research. The authors would like to express their sincere thanks to the support of Taif University Researchers Supporting Project Number (TURSP-2020/217), Taif University, Taif, Saudi Arabia.



    Conflict of interest



    The authors declare no conflicts of interest.

    [1] Masrori P, Van Damme P (2020) Amyotrophic lateral sclerosis: a clinical review. Eur J Neurol 27: 1918-1929. https://doi.org/10.1111/ene.14393
    [2] Tzeplaeff L, Wilfling S, Requardt MV, et al. (2023) Current State and Future Directions in the Therapy of ALS. Cells 12: 1523. https://doi.org/10.3390/cells12111523
    [3] Blair HA (2023) Tofersen: First Approval. Drugs 83: 1039-1043. https://doi.org/10.1007/s40265-023-01904-6
    [4] Benedetto Tiz D, Bagnoli L, Rosati O, et al. (2022) FDA-Approved Small Molecules in 2022: Clinical Uses and Their Synthesis. Pharmaceutics 14: 2538. https://doi.org/10.3390/pharmaceutics14112538
    [5] Neupane P, Thada PK, Singh P, et al. (2023) Investigating Edaravone Use for Management of Amyotrophic Lateral Sclerosis (ALS): A Narrative Review. Cureus 15: e33746. https://doi.org/10.7759/cureus.33746
    [6] Bellingham MC (2011) A review of the neural mechanisms of action and clinical efficiency of riluzole in treating amyotrophic lateral sclerosis: what have we learned in the last decade?. CNS Neurosci Ther 17: 4-31. https://doi.org/10.1111/j.1755-5949.2009.00116.x
    [7] Brooks BR, Bettica P, Cazzaniga S (2019) Riluzole Oral Suspension: Bioavailability Following Percutaneous Gastrostomy Tube-modeled Administration Versus Direct Oral Administration. Clin Ther 41: 2490-2499. https://doi.org/10.1016/j.clinthera.2019.09.016
    [8] Wymer J, Apple S, Harrison A, et al. (2023) Pharmacokinetics, Bioavailability, and Swallowing Safety With Riluzole Oral Film. Clin Pharmacol Drug Dev 12: 57-64. https://doi.org/10.1002/cpdd.1168
    [9] Sun Y, Benatar M, Mascías Cadavid J, et al. (2023) ALSUntangled #71: Nuedexta. Amyotroph Lateral Scler Frontotemporal Degener 26: 1-5. https://doi.org/10.1080/21678421.2023.2239292
    [10] Eleutherio ECA, Silva Magalhães RS, de Araújo Brasil A, et al. (2021) SOD1, more than just an antioxidant. Arch Biochem Biophys 697: 108701. https://doi.org/10.1016/j.abb.2020.108701
    [11] Bunton-Stasyshyn RKA, Saccon RA, Fratta P, et al. (2015) SOD1 function and its implications for amyotrophic lateral sclerosis pathology: New and renascent themes. Neuroscientist 21: 519-529. https://doi.org/10.1177/1073858414561795
    [12] Rinaldi C, Wood MJA (2018) Antisense oligonucleotides: the next frontier for treatment of neurological disorders. Nat Rev Neurol 14: 9-21. https://doi.org/10.1038/nrneurol.2017.148
    [13] Miller TM, Cudkowicz ME, Genge A, et al. (2022) Trial of antisense oligonucleotide tofersen for SOD1 ALS. N Engl J Med 387: 1099-1110. https://doi.org/10.1056/NEJMoa2204705
    [14] Blair HA (2023) Tofersen: First approval. Drugs 83: 1039-1043. https://doi.org/10.1007/s40265-023-01904-6
    [15] Miller T, Cudkowicz M, Shaw PJ, et al. (2020) Phase 1–2 trial of antisense oligonucleotide tofersen for SOD1 ALS. N Engl J Med 383: 109-119. https://doi.org/10.1056/NEJMoa2003715
    [16] Benatar M, Wuu J, Andersen PM, et al. (2022) Design of a randomized, placebo-controlled, phase 3 trial of tofersen initiated in clinically presymptomatic SOD1 variant carriers: The ATLAS study. Neurotherapeutics 19: 1248-1258. https://doi.org/10.1007/s13311-022-01237-4
    [17] Fels JA, Dash J, Leslie K, et al. (2022) Effects of the Investigational Drug Sodium Phenylbutyrate-TUDCA (AMX0035) on the Transcriptional and Metabolic Landscape of Sporadic ALS Fibroblasts. Neuroscience . https://doi.org/10.1101/2022.05.02.490306
    [18] Mead RJ, Shan N, Reiser HJ, et al. (2023) Amyotrophic lateral sclerosis: a neurodegenerative disorder poised for successful therapeutic translation. Nat Rev Drug Discov 22: 185-212. https://doi.org/10.1038/s41573-022-00612-2
    [19] Soares R, Ribeiro FF, Xapelli S, et al. (2018) Tauroursodeoxycholic Acid Enhances Mitochondrial Biogenesis, Neural Stem Cell Pool, and Early Neurogenesis in Adult Rats. Mol Neurobiol 55: 3725-3738. https://doi.org/10.1007/s12035-017-0592-5
    [20] Yam GHF, Gaplovska-Kysela K, Zuber C, et al. (2007) Sodium 4-phenylbutyrate acts as a chemical chaperone on misfolded myocilin to rescue cells from endoplasmic reticulum stress and apoptosis. Invest Ophthalmol Vis Sci 48: 1683. https://doi.org/10.1167/iovs.06-0943
    [21] Sodium Phenylbutyrate and TaurursodiolAmerican Journal of Health-System Pharmacy (2023)80: 316-318. https://doi.org/10.1093/ajhp/zxac363
    [22] Paganoni S, Macklin EA, Hendrix S, et al. (2020) Trial of Sodium Phenylbutyrate–Taurursodiol for Amyotrophic Lateral Sclerosis. N Engl J Med 383: 919-930. https://doi.org/10.1056/NEJMoa1916945
    [23] Cho H, Shukla S (2020) Role of edaravone as a treatment option for patients with amyotrophic Lateral Sclerosis. Pharmaceuticals (Basel) 14: 29. https://doi.org/10.3390/ph14010029
    [24] Beal MF, Ferrante RJ, Browne SE, et al. (1997) Increased 3-nitrotyrosine in both sporadic and familial amyotrophic lateral sclerosis. Ann Neurol 42: 644-654. https://doi.org/10.1002/ana.410420416
    [25] Cipak Gasparovic A, Zarkovic N, Zarkovic K, et al. (2017) Biomarkers of oxidative and nitro-oxidative stress: conventional and novel approaches. Br J Pharmacol 174: 1771-1783. https://doi.org/10.1111/bph.13673
    [26] Yamamoto Y, Kuwahara T, Watanabe K, et al. (1996) Antioxidant activity of 3-methyl-1-phenyl-2-pyrazolin-5-one. Redox Rep 2: 333-338. https://doi.org/10.1080/13510002.1996.11747069
    [27] Jami MS, Salehi-Najafabadi Z, Ahmadinejad F, et al. (2015) Edaravone leads to proteome changes indicative of neuronal cell protection in response to oxidative stress. Neurochem Int 90: 134-141. https://doi.org/10.1016/j.neuint.2015.07.024
    [28] PubChem. PRDX2 - peroxiredoxin 2 (human). Accessed December 30, 2023. Available from: https://pubchem.ncbi.nlm.nih.gov/gene/PRDX2/human
    [29] Yoshino H, Kimura A (2006) Investigation of the therapeutic effects of edaravone, a free radical scavenger, on amyotrophic lateral sclerosis (Phase II study). Amyotroph Lateral Scler 7: 241-245. https://doi.org/10.1080/17482960600881870
    [30] Abe K, Itoyama Y, Sobue G, et al. (2014) Confirmatory double-blind, parallel-group, placebo-controlled study of efficacy and safety of edaravone (MCI-186) in amyotrophic lateral sclerosis patients. Amyotroph Lateral Scler Frontotemporal Degener 15: 610-617. https://doi.org/10.3109/21678421.2014.959024
    [31] THE EDARAVONE (MCI-186) ALS 16 STUDY GROUP.A post-hoc subgroup analysis of outcomes in the first phase III clinical study of edaravone (MCI-186) in amyotrophic lateral sclerosis. Amyotroph Lateral Scler Frontotemporal Degener (2017) 18(sup1): 11-19. https://doi.org/10.1080/21678421.2017.1363780
    [32] Writing Group, Edaravone (MCI-186) ALS 19 Study Group.Safety and efficacy of edaravone in well defined patients with amyotrophic lateral sclerosis: a randomized, double-blind, placebo-controlled trial. Lancet Neurol (2017) 16: 505-512. https://doi.org/10.1016/S1474-4422(17)30115-1
    [33] Fda.gov. Accessed January 11, 2024. Available from: https://www.accessdata.fda.gov/drugsatfda_docs/label/2009/020599s011s012lbl.pdf
    [34] Rattray M, Bendotti C (2006) Does excitotoxic cell death of motor neurons in ALS arise from glutamate transporter and glutamate receptor abnormalities?. Exp Neurol 201: 15-23. https://doi.org/10.1016/j.expneurol.2006.05.001
    [35] Zona C, Siniscalchi A, Mercuri NB, et al. (1998) Riluzole interacts with voltage-activated sodium and potassium currents in cultured rat cortical neurons. Neuroscience 85: 931-938. https://doi.org/10.1016/S0306-4522(97)00604-0
    [36] Liu AYC, Mathur R, Mei N, et al. (2011) Neuroprotective drug riluzole amplifies the heat shock factor 1 (HSF1)- and glutamate transporter 1 (GLT1)-dependent cytoprotective mechanisms for neuronal survival. J Biol Chem 286: 2785-2794. https://doi.org/10.1074/jbc.M110.158220
    [37] Foran E, Trotti D (2009) Glutamate transporters and the excitotoxic path to motor neuron degeneration in amyotrophic lateral sclerosis. Antioxid Redox Signal 11: 1587-1602. https://doi.org/10.1089/ars.2009.2444
    [38] Bensimon G, Lacomblez L, Meininger V (1994) A controlled trial of riluzole in amyotrophic lateral sclerosis. ALS/Riluzole Study Group. N Engl J Med 330: 585-591. https://doi.org/10.1056/NEJM199403033300901
    [39] Lacomblez L, Bensimon G, Leigh PN, et al. (1996) Dose-ranging study of riluzole in amyotrophic lateral sclerosis. Amyotrophic Lateral Sclerosis/Riluzole Study Group II. Lancet 347: 1425-1431. https://doi.org/10.1016/S0140-6736(96)91680-3
    [40] Takei K, Tsuda K, Takahashi F, et al. (2017) An assessment of treatment guidelines, clinical practices, demographics, and progression of disease among patients with amyotrophic lateral sclerosis in Japan, the United States, and Europe. Amyotroph Lateral Scler Frontotemporal Degener 18: 88-97. https://doi.org/10.1080/21678421.2017.1361445
    [41] Inácio P (2023) Early 2024 eyed for approval decision in EU on masitinib for ALS. ALS News Today . Available from: https://alsnewstoday.com/news/early-2024-likely-masitinib-eu-conditional-approval-decision-als/
    [42] Mora JS, Genge A, Chio A, et al. (2020) Masitinib as an add-on therapy to riluzole in patients with amyotrophic lateral sclerosis: a randomized clinical trial. Amyotroph Lateral Scler Frontotemporal Degener 21: 5-14. https://doi.org/10.1080/21678421.2019.1632346
    [43] An S, Lee W, Yoo B (2023) Comparison of national dysphagia diet and international dysphasia diet standardization initiative levels for thickened drinks prepared with a commercial xanthan gum-based thickener used for patients with dysphagia. Prev Nutr Food Sci 28: 83-88. https://doi.org/10.3746/pnf.2023.28.1.83
    [44] Povedano Panades M, Couratier P, Sidle K, et al. (2021) Administration of riluzole oral suspension during the different stages of amyotrophic lateral sclerosis. Front Neurol 12. https://doi.org/10.3389/fneur.2021.633854
    [45] Brooks BR, Bettica P, Cazzaniga S (2019) Riluzole oral suspension: Bioavailability following percutaneous gastrostomy tube-modeled administration versus direct oral administration. Clin Ther 41: 2490-2499. https://doi.org/10.1016/j.clinthera.2019.09.016
    [46] Keating GM (2016) Riluzole oral suspension in amyotrophic lateral sclerosis: a guide to its use. Drugs Ther Perspect 32: 282-286. https://doi.org/10.1007/s40267-016-0312-7
    [47] Onesti E, Schettino I, Gori MC, et al. (2017) Dysphagia in amyotrophic lateral sclerosis: Impact on patient behavior, diet adaptation, and riluzole management. Front Neurol 8. https://doi.org/10.3389/fneur.2017.00094
    [48] Calvo AC, Valledor-Martín I, Moreno-Martínez L, et al. (2022) Lessons to Learn from the Gut Microbiota: A Focus on Amyotrophic Lateral Sclerosis. Genes (Basel) 13: 865. https://doi.org/10.3390/genes13050865
    [49] Bissaro M, Moro S (2019) Rethinking to riluzole mechanism of action: the molecular link among protein kinase CK1δ activity, TDP-43 phosphorylation, and amyotrophic lateral sclerosis pharmacological treatment. Neural Regen Res 14: 2083-2085. https://doi.org/10.4103/1673-5374.262578
    [50] Drug and Device News. P T 43: 588-598.
    [51] Oh SR, Agrawal S, Sabir S, et al. (2023) Dextromethorphan. [Updated 2023 May 22]. StatPearls [Internet] . Treasure Island (FL): StatPearls Publishing. Available from: https://www.ncbi.nlm.nih.gov/books/NBK538216/
    [52] Jain A, SISODIA J (2023) Quinidine. StatPearls . Treasure Island (FL): StatPearls Publishing.
    [53] Cruz MP (2013) Nuedexta for the treatment of pseudobulbar affect: a condition of involuntary crying or laughing. P T 38: 325-328.
    [54] Ahmed A, Simmons Z (2013) Pseudobulbar affect: prevalence and management. Ther Clin Risk Manag 9: 483-489. https://doi.org/10.2147/TCRM.S53906
  • This article has been cited by:

    1. Mohammed Shehu Shagari, Qiu-Hong Shi, Saima Rashid, Usamot Idayat Foluke, Khadijah M. Abualnaja, Fixed points of nonlinear contractions with applications, 2021, 6, 2473-6988, 9378, 10.3934/math.2021545
    2. Farhat Safdar, Muhammad Attique, Some new generalizations for exponentially (s, m)-preinvex functions considering generalized fractional integral operators, 2021, 1016-2526, 861, 10.52280/pujm.2021.531203
    3. Shuang-Shuang Zhou, Saima Rashid, Erhan Set, Abdulaziz Garba Ahmad, Y. S. Hamed, On more general inequalities for weighted generalized proportional Hadamard fractional integral operator with applications, 2021, 6, 2473-6988, 9154, 10.3934/math.2021532
    4. Saima Rashid, Aasma Khalid, Omar Bazighifan, Georgia Irina Oros, New Modifications of Integral Inequalities via ℘-Convexity Pertaining to Fractional Calculus and Their Applications, 2021, 9, 2227-7390, 1753, 10.3390/math9151753
    5. Saima Rashid, Fahd Jarad, Khadijah M. Abualnaja, On fuzzy Volterra-Fredholm integrodifferential equation associated with Hilfer-generalized proportional fractional derivative, 2021, 6, 2473-6988, 10920, 10.3934/math.2021635
    6. SAIMA RASHID, ELBAZ I. ABOUELMAGD, AASMA KHALID, FOZIA BASHIR FAROOQ, YU-MING CHU, SOME RECENT DEVELOPMENTS ON DYNAMICAL ℏ-DISCRETE FRACTIONAL TYPE INEQUALITIES IN THE FRAME OF NONSINGULAR AND NONLOCAL KERNELS, 2022, 30, 0218-348X, 10.1142/S0218348X22401107
    7. Wengui Yang, Certain New Chebyshev and Grüss-Type Inequalities for Unified Fractional Integral Operators via an Extended Generalized Mittag-Leffler Function, 2022, 6, 2504-3110, 182, 10.3390/fractalfract6040182
    8. Shuang-Shuang Zhou, Saima Rashid, Asia Rauf, Khadija Tul Kubra, Abdullah M. Alsharif, Initial boundary value problems for a multi-term time fractional diffusion equation with generalized fractional derivatives in time, 2021, 6, 2473-6988, 12114, 10.3934/math.2021703
    9. Songkran Pleumpreedaporn, Chanidaporn Pleumpreedaporn, Weerawat Sudsutad, Jutarat Kongson, Chatthai Thaiprayoon, Jehad Alzabut, On a novel impulsive boundary value pantograph problem under Caputo proportional fractional derivative operator with respect to another function, 2022, 7, 2473-6988, 7817, 10.3934/math.2022438
    10. SAIMA RASHID, AASMA KHALID, YELIZ KARACA, YU-MING CHU, REVISITING FEJÉR–HERMITE–HADAMARD TYPE INEQUALITIES IN FRACTAL DOMAIN AND APPLICATIONS, 2022, 30, 0218-348X, 10.1142/S0218348X22401338
    11. Bounmy Khaminsou, Weerawat Sudsutad, Jutarat Kongson, Somsiri Nontasawatsri, Adirek Vajrapatkul, Chatthai Thaiprayoon, Investigation of Caputo proportional fractional integro-differential equation with mixed nonlocal conditions with respect to another function, 2022, 7, 2473-6988, 9549, 10.3934/math.2022531
    12. Fuxiang Liu, Jielan Li, Analytical Properties and Hermite–Hadamard Type Inequalities Derived from Multiplicative Generalized Proportional σ-Riemann–Liouville Fractional Integrals, 2025, 17, 2073-8994, 702, 10.3390/sym17050702
  • Reader Comments
  • © 2024 the Author(s), licensee AIMS Press. This is an open access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0)
通讯作者: 陈斌, bchen63@163.com
  • 1. 

    沈阳化工大学材料科学与工程学院 沈阳 110142

  1. 本站搜索
  2. 百度学术搜索
  3. 万方数据库搜索
  4. CNKI搜索

Metrics

Article views(1711) PDF downloads(82) Cited by(3)

/

DownLoad:  Full-Size Img  PowerPoint
Return
Return

Catalog